



Solving the airway management challenge with simplicity

- Novel
- Patented
- Accessible
- Disruptive

This document contains forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions and current expectations, which could cause the Company's actual results to differ materially from those anticipated in such forward-looking statements. You should not rely on forward-looking statements as guarantees, assurances or predictions of future events. This document is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company

©2025 Epic Airway Systems, Inc. All rights reserved.




Problem

Peri-Operative

Procedures are more complex

Pre-Hospital

Skill erosion impacting patient outcomes



Solution

All-in-one transitional
airway management device



- ✓ Broad IP Protection
- ✓ No Clinical Trials
- ✓ No new Insurance Codes
- ✓ No experience needed



>75%
GM


Value

Peri-Operative

Procedures simplified & supported

Pre-Hospital

Improved success rate & patient outcomes



Competition



i-Gel SGA & generic ETT **LMA Fastrach® & ETT**
(sold separately)

Epic Airway®

Device offering simplicity & security

×

×

✓

Transition without breathing interruption

×

×

✓

Staged intubation, extubation & less “bucking”

×

✓

✓

Total “transitional procedure” Cost (LM to ETT)

Includes: device, support devices, pharmaceuticals & labor/OR costs


\$2150

\$2000

\$650

Protection

Addressing 20 years of stagnant airway innovation



Design, Method & Utility

- ✔ US – 4 issued; 3 in-process
- ✔ EU – 2 granted; 8 validations
- ✔ Offensive | Defensive | Next-Gen

Trademark


- ✔ Registered EPIC Airway®

Freedom To Operate

- ✔ Initial FTO complete
- ✔ Final FTO Q4/2025


Market Size

(units)



(1) Allied Market Research; "Global Airway Management Devices Market" 12/2023

Go to Market



Commercialization

Regions

Hospital Dense
US States

Segments

Peri-Hospital

Applications

Specialty Surgeries
& Adult Intubations

Marketing & Sales

YEAR 1

Launch & clinical
"Friends of Epic"

YEAR 2

Scale for broad
national adoption
(B2B)

YEAR 3

Distributor Driven |
Global Expansion |
Reusable Launch

Financials

\$10M

Post Money Valuation

\$500M


5-Year Valuation
Post- Commercialization

3Q2026

Projected Commercial Launch



75%
GM



(1) Y1 thru Y5 represent the five 365-day periods, post commercial launch

Exit



- 2016 VivaSight FDA 510(k) Cleared
- 2016 Ambu Acquisition [pre-revenue]
- \$16M Valuation [\$22M adjusted]

Y1

 Launch
Rev: \$2.2M
Val: \$22M⁽¹⁾

Y3

 Profitability
Rev: \$17.4M
Val: \$57M⁽²⁾

Y5

 Mrkt. Conv.
Rev: \$106M
Val: \$505M⁽²⁾

Meet our Team



Eric Moses
MD, MBA
CEO, CMO
Co-Founder, BOD



Keith McKenna
COO, CFO
BOD



Sridhar Musuku
MD
Director of Innovation
Co-Founder, BOD



Chris Wilson
Lead: QA/RA | Strategy



Robert Sawyer
CPA, CMA, MBA
Fractional CFO



Ana Galeano
ESQ
Legal Counsel



Adrienne Harris
MS
Lead: Design & Eng.



Jim Komsa
Advisor: Sales



Scott Brown
MS, MBA
Advisor: Marketing



Cara Maryanopolis
MS
Lead: Brand | Media



Andrew Gano
MBA
Advisor: Strategy



Stephen Harper
MD, DCOM US Army
Advisor: Clinical | EMS



Dan Mayer
MD, Fellow AAEM
Advisor: Clinical | ER



Low-Cost Domestic Production



Detailed Design & FDA 510(k)



Pre-Clinical Validation




NOTE: Advisory members engaged; formal advisory agreements evolving

Progression

- 5 Years of Development
- 27 Design Iterations



Traction




Use of Funds & Ask

Product Commercialization



Use of Funds

- ✓ Design V&V Testing | FDA 510(k)
- ✓ Tooling & Process Dev. & Val.
- ✓ Clinical Simulation Testing
- ✓ IP & Legal (on-going)
- ✓ Launch Inventory
- ✓ Pre-Commercial Market Dev.
- ✓ Operational Infrastructure | SG&A



\$1,385,000

Cumulative Equity Raised
Friends & Family

\$4M (Current)

Common Stock Fixed Equity

Q2/2026

Closing Round



Creating
innovation with
low-tech airway
products

 investor@epicairwaysystems.com

 www.epicairwaysystems.com



DISCLAIMER/CAUTIONARY STATEMENT

The purpose of the information in this presentation ("Presentation") is to describe the material aspects of the current and projected business of Epic Airway Systems, Inc., a Delaware corporation ("Company"). Receipt and acceptance of this Presentation (including viewing this Presentation as part of an oral presentation by the principals or authorized agents of the Company) shall constitute an agreement by you (the "Recipient") that, among other things, this Presentation shall not in any manner whatsoever be copied, reproduced, modified, or distributed to any third party, either in whole or in part, without the prior written consent of the Company. All information contained herein shall be kept confidential by the Recipient, and the Recipient shall not reveal or disclose to any third party without written consent of the Company the information that has been made available to the Recipient.

While the information set forth in the Presentation is deemed by the Company to be accurate, the Company shall not be held liable for the accuracy of, or omissions from, this Presentation and for any other written or oral communication transmitted to the Recipient and any other party in the course of its evaluation of transactions involving the Company. It should be understood that all information provided in this Presentation is provided "AS IS" without warranty of any kind. In particular, the Company may not update this Presentation on a daily or other regular basis. As such, the information and materials contained in this Presentation may be out of date or include omissions or other errors. In addition, the Company may change the information provided in this Presentation at any time without notice and the Company will not be liable in any way for possible consequences of such changes.

This Presentation may contain forward-looking statements, including statements about the Company's beliefs and expectations and/or the Company's products and services. These statements are based on current plans, estimates and projections that are subject to significant economic, business, and other uncertainties beyond the Company's control, and therefore Recipients should not place undue reliance on them and the Company makes no representations as to their attainability.

Nothing in this Presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares of the Company in any jurisdiction.